These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 35580927)

  • 1. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
    Rejeski K; Perez A; Iacoboni G; Penack O; Bücklein V; Jentzsch L; Mougiakakos D; Johnson G; Arciola B; Carpio C; Blumenberg V; Hoster E; Bullinger L; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Barba P; Jain MD; Subklewe M
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.
    Rejeski K; Hansen DK; Bansal R; Sesques P; Ailawadhi S; Logue JM; Bräunlein E; Cordas Dos Santos DM; Freeman CL; Alsina M; Theurich S; Wang Y; Krackhardt AM; Locke FL; Bachy E; Jain MD; Lin Y; Subklewe M
    J Hematol Oncol; 2023 Jul; 16(1):88. PubMed ID: 37525244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
    Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
    Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
    Rejeski K; Wang Y; Albanyan O; Munoz J; Sesques P; Iacoboni G; Lopez-Corral L; Ries I; Bücklein VL; Mohty R; Dreyling M; Baluch A; Shah B; Locke FL; Hess G; Barba P; Bachy E; Lin Y; Subklewe M; Jain MD
    Am J Hematol; 2023 Nov; 98(11):1699-1710. PubMed ID: 37584447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.
    Sýkorová A; Folber F; Polgárová K; Móciková H; Ďuraš J; Steinerová K; Obr A; Heindorfer A; Ladická M; Lukáčová Ľ; Čellárová E; Plameňová I; Belada D; Janíková A; Trněný M; Jančárková T; Procházka V; Vranovský A; Králiková M; Vydra J; Smolej L; Drgoňa Ľ; Sedmina M; Čermáková E; Pytlík R
    Cancer Med; 2024 Sep; 13(17):e70138. PubMed ID: 39248284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of
    Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
    J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.
    Bailén R; Iacoboni G; Delgado J; López-Corral L; Hernani-Morales R; Ortiz-Maldonado V; Guerreiro M; Caballero AC; Guerra-Domínguez ML; Sánchez-Pina JM; Peña M; Torrent A; Pérez-Martínez A; Bastos-Oreiro M; Reguera-Ortega JL; Martín A; Hernandez-Boluda JC; Martínez-Cibrián N; Sanz J; Briones J; Henriquez HL; Calbacho M; Mussetti A; Sancho JM; Barba P; Kwon M;
    Transplant Cell Ther; 2024 Oct; 30(10):988.e1-988.e11. PubMed ID: 39069076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.
    Liang Y; Liu H; Lu Z; Lei W; Zhang C; Li P; Liang A; Young KH; Qian W
    J Hematol Oncol; 2021 Feb; 14(1):26. PubMed ID: 33593414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
    Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
    J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
    Miller A; Daum R; Wang T; Wu M; Tat C; Pfeiffer T; Navai S; Heczey A; Hegde M; Ahmed N; Whittle SB; Hill L; Martinez C; Krance R; Ramos CA; Rouce RH; Lulla P; Heslop HE; Omer B; Shekar M
    Cytotherapy; 2024 Sep; 26(9):1026-1032. PubMed ID: 38819365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
    Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
    Front Immunol; 2021; 12():755549. PubMed ID: 34777367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
    Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
    Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
    Beyar Katz O; Perry C; Grisariu-Greenzaid S; Yehudai-Ofir D; Luttwak E; Avni B; Zuckerman T; Sdayoor I; Stepensky P; Ringelstein-Harlev S; Bar-On Y; Libster D; Sharvit L; Amit O; Greenbaum U; Gold R; Herishanu Y; Benyamini N; Avivi I; Ram R
    Eur J Haematol; 2023 Jul; 111(1):63-71. PubMed ID: 36964939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
    Shargian L; Raanani P; Yeshurun M; Gafter-Gvili A; Gurion R
    Br J Haematol; 2022 Sep; 198(5):838-846. PubMed ID: 35765220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study.
    Tun AM; Patel RD; St-Pierre F; Ouchveridze E; Niu A; Thordardottir T; Obasi J; Rosenthal A; Pophali PA; Fenske TS; Karmali R; Ahmed S; Johnston PB
    Am J Hematol; 2024 Sep; 99(9):1712-1720. PubMed ID: 38837403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
    Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis.
    Pernas B; Iacoboni G; Los-Arcos I; Carpio C; Márquez-Algaba E; Sanchez-Salinas MA; Albasanz A; Esperalba J; Viñado B; Camps IR; Barba P
    Eur J Haematol; 2024 Aug; 113(2):227-234. PubMed ID: 38665060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.